Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.64 |
| ▸ | HTR1A | P08908 | 3/20 | 0.64 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.64 |
| ▸ | HTR7 | P34969 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTR5A | P47898 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5250896 | 0.99 | HTR2A (0.63) | HTR2AHTR1ATMEM97HTR7RAB9A | |
| SCHEMBL5252657 | 0.95 | HTR2A (0.63) | HTR2AHTR1ATMEM97HTR7RAB9A | |
| Hydrochloric Acid SCHEMBL5249764 | 0.94 | HTR2A (0.62) | HTR2AHTR1ATMEM97HTR7ACHE | |
| SCHEMBL5254157 | 0.94 | HTR2A (0.62) | HTR2AHTR1ATMEM97HTR7ACHE | |
| Hydrochloric Acid SCHEMBL5252130 | 0.93 | HTR2A (0.61) | HTR2AHTR1ATMEM97HTR7ACHE | |
| SCHEMBL5249839 | 0.91 | ACHE (0.55) | HTR2AHTR1ATMEM97HTR7ACHE | |
| SCHEMBL5248701 | 0.90 | HTR7 (0.52) | HTR2AHTR1ATMEM97HTR7ACHE | |
| SCHEMBL5251809 | 0.90 | HTR2A (0.52) | HTR2AHTR1ATMEM97HTR7ACHE | |
| SCHEMBL5252497 | 0.90 | TMEM97 (0.51) | HTR2AHTR1ATMEM97HTR7RAB9A | |
| SCHEMBL5251606 | 0.89 | HTR1A (0.56) | HTR2AHTR1ATMEM97HTR7ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1260512-B1 | NOVEL CYCLIC AMIDE DERIVATIVES | MITSUBISHI PHARMA CORP (JP) | 2007-07-04 | — | — | EP | disclosed |
| US-7166617-B2 | Cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-01-23 | — | — | US | disclosed |
| US-20030212094-A1 | Novel cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1260512-A1 | NOVEL CYCLIC AMIDE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2002-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212094-A1 | Novel cyclic amide derivatives | SIGMAR1, OPRM1, OPRD1 | HTR2A 153/4885HTR1A 79/4885TMEM97 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.